[ad_1]
Patent expiries, new brand launches, and better geographical penetration have helped Indian pharma companies report better growth rates and a higher share of the domestic market in the last five years. Multinational companies (MNCs), on the other hand, are focussing on niche therapies, going for licensing deals with Indian firms to get a wider reach, and bringing in more innovative global products.
Take Novartis, for instance. “To ensure that we are truly focused and efficient, we have narrowed down on our priority disease areas for India where we can win and create most value,” Amitabh Dube, country president and managing
First Published: Jan 25 2024 | 12:38 AM IST
[ad_2]